Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX).
Saved in:
| Title: | Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX). |
|---|---|
| Authors: | Pathak P; Department of Radiation Oncology, Baylor College of Medicine, Houston, TX, United States., Jo E; Department of Biostatistics, Baylor College of Medicine, Houston, TX, United States., Hilsenbeck S; Department of Biostatistics, Baylor College of Medicine, Houston, TX, United States., Anderson ML; Department of Obstetrics and Gynecology, University of South Florida (USF) Morsani College of Medicine, Tampa, FL, United States., Echeverria A; Department of Radiation Oncology, Baylor College of Medicine, Houston, TX, United States., Sharma S; Department of Radiation Oncology, Baylor College of Medicine, Houston, TX, United States., Sunde J; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, United States., Hall T; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, United States., Costales A; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, United States., Hoppenot C; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, United States., Ludwig M; Department of Radiation Oncology, Baylor College of Medicine, Houston, TX, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Mar 09; Vol. 16, pp. 1677424. Date of Electronic Publication: 2026 Mar 09 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
